Mabuchi M - Search Results

1

Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, Kamiyama H, Takahashi K, Kotake Y, Uesugi M, Yokoi A, Inoue A, Yoshida T, Mabuchi M, Tanaka A, Owa T. Uehara T, et al. Among authors: mabuchi m. Nat Chem Biol. 2017 Jun;13(6):675-680. doi: 10.1038/nchembio.2363. Epub 2017 Apr 24. Nat Chem Biol. 2017. PMID: 28437394

2

Selective elution of target protein from affinity resins by a simple reductant with a thiol group.

Mabuchi M, Haramura M, Shimizu T, Nishizaki T, Tanaka A. Mabuchi M, et al. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7361-4. doi: 10.1016/j.bmcl.2010.10.053. Epub 2010 Oct 19. Bioorg Med Chem Lett. 2010. PMID: 21067925

3

Improvement of solid material for affinity resins by application of long PEG spacers to capture the whole target complex of FK506.

Mabuchi M, Shimizu T, Ueda M, Mitamura K, Ikegawa S, Tanaka A. Mabuchi M, et al. Bioorg Med Chem Lett. 2015 Jul 15;25(14):2788-92. doi: 10.1016/j.bmcl.2015.05.014. Epub 2015 May 15. Bioorg Med Chem Lett. 2015. PMID: 26025877

4

Identification and purification of target protein using affinity resin bearing a photo-labile linker.

Mabuchi M, Shimizu T, Haramura M, Tanaka A. Mabuchi M, et al. Bioorg Med Chem Lett. 2015 Aug 15;25(16):3373-7. doi: 10.1016/j.bmcl.2015.05.023. Epub 2015 May 16. Bioorg Med Chem Lett. 2015. PMID: 26099537

5

DCP-LA Activates Cytosolic PKCε by Interacting with the Phosphatidylserine Binding/Associating Sites Arg50 and Ile89 in the C2-Like Domain.

Kanno T, Tsuchiya A, Shimizu T, Mabuchi M, Tanaka A, Nishizaki T. Kanno T, et al. Among authors: mabuchi m. Cell Physiol Biochem. 2015;37(1):193-200. doi: 10.1159/000430344. Epub 2015 Aug 20. Cell Physiol Biochem. 2015. PMID: 26289043 Free article.

6

Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.

Mabuchi M, Ueda M, Yoshida Y, Horiike K, Yamaoka K, Nakao S, Shimizu T, Ueda Y, Tsujikawa K, Tanaka A. Mabuchi M, et al. Anticancer Res. 2017 Apr;37(4):1665-1676. doi: 10.21873/anticanres.11496. Anticancer Res. 2017. PMID: 28373427

7

Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.

Nakao S, Mabuchi M, Wang S, Kogure Y, Shimizu T, Noguchi K, Tanaka A, Dai Y. Nakao S, et al. Among authors: mabuchi m. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3167-3172. doi: 10.1016/j.bmcl.2017.05.025. Epub 2017 May 22. Bioorg Med Chem Lett. 2017. PMID: 28576617

8

Novel Metabolically Stable PCA-1/ALKBH3 Inhibitor Has Potent Antiproliferative Effects on DU145 Cells In Vivo.

Ueda M, Shimizu T, Mabuchi M, Horiike K, Kitae K, Hase H, Ueda Y, Tsujikawa K, Tanaka A. Ueda M, et al. Among authors: mabuchi m. Anticancer Res. 2018 Jan;38(1):211-218. doi: 10.21873/anticanres.12210. Anticancer Res. 2018. PMID: 29277775

9

Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug.

Shimizu T, Yamaguchi K, Yamamoto M, Kurioka R, Kino Y, Matsunaga W, Nakao S, Fukuhara H, Tanaka A, Gotoh A, Mabuchi M. Shimizu T, et al. Among authors: mabuchi m. Bioorg Med Chem Lett. 2020 Jan 1;30(1):126744. doi: 10.1016/j.bmcl.2019.126744. Epub 2019 Nov 8. Bioorg Med Chem Lett. 2020. PMID: 31759851

10

Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo.

Mabuchi M, Tsujikawa K, Tanaka A. Mabuchi M, et al. Anticancer Drugs. 2025 Jan 1;36(1):19-27. doi: 10.1097/CAD.0000000000001656. Epub 2024 Aug 26. Anticancer Drugs. 2025. PMID: 39259581

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters